Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.
Ludovico ArcuriSalvatore NovelloMartina FrassinetiDaniela MercatelliClarissa Anna PisanòIlaria MorellaStefania FasanoBlair V JourniganMichael E MeyerWillma E PolgarRiccardo BrambillaNurulain T ZaveriMichele MorariPublished in: British journal of pharmacology (2018)
NOP receptor stimulation can provide significant albeit mild anti-dyskinetic effect at doses not causing sedation. The therapeutic window, however, varies across compounds. AT-403 could be a potent and selective tool to investigate the role of NOP receptors in vivo.